Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.38 |
| ▸ | PPARD | Q03181 | 8/20 | 0.38 |
| ▸ | PPARG | P37231 | 7/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043470 | 0.89 | CARM1 (0.37) | PTGER4PTGER2HPGDFFAR1CARM1 | |
| SCHEMBL5042627 | 0.89 | CARM1 (0.37) | PTGER4PTGER2HPGDFFAR1CARM1 | |
| SCHEMBL5043475 | 0.89 | CARM1 (0.37) | PTGER4PTGER2HPGDFFAR1CARM1 | |
| SCHEMBL5040434 | 0.77 | FFAR1 (0.34) | PPARAPPARGFFAR1 | |
| Hydrochloric Acid SCHEMBL5037746 | 0.75 | CARM1 (0.46) | PPARAPPARDPPARGPTGER4PTGER2 | |
| Hydrochloric Acid SCHEMBL5037743 | 0.75 | CARM1 (0.46) | PPARAPPARDPPARGPTGER4PTGER2 | |
| Hydrochloric Acid SCHEMBL5037748 | 0.75 | CARM1 (0.46) | PPARAPPARDPPARGPTGER4PTGER2 | |
| SCHEMBL5042596 | 0.74 | PPARA (0.33) | PPARAPPARDPPARGFFAR1 | |
| SCHEMBL5041275 | 0.72 | LDHA (0.40) | PPARAPPARDPPARGHPGDFFAR1 | |
| SCHEMBL24327731 | 0.72 | HPGD (0.49) | PPARAPPARGHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | PPARA 4124/4885PPARD 4571/4885PPARG 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.